Roche to Acquire Digital Pathology Firm PathAI for up to $1B

Roche has begun an agreement to acquire PathAI, a U.S.-based company that specializes in digital pathology and artificial intelligence (AI)-powered technology for pathology labs and the biopharma industry.

Under the agreement’s terms, Roche will pay a purchase price of $750 million upfront and further milestone payments of up to $300 million.

The companies began a partnership in 2021 and scaled it up in 2024 to include development of AI-enabled companion diagnostic algorithms. Once the transaction closes, which is expected in the second half of the year, PathAI will become part of Roche’s Diagnostics division.

The deal bolters Roche’s position in digital pathology, which is changing extensive manual workflows into fully automated, AI-driven processes and insights. Digital pathology allows creation of high-resolution digital images from physical tissue on slides so pathologists can use AI tools to facilitate diagnostic workflows and provide results more quickly.

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” said Matt Sause, CEO of Roche Diagnostics. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”

PathAI’s AISight IMS software integrates advanced analysis and workflow capabilities in the digital pathology lab. Due to the rapidly growing pathology market, Roche said it plans to scale this solution globally.

“Joining forces with Roche marks a new era for PathAI, enabling us to realize our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed,” said PathAI’s co-founder and CEO Andy Beck. “Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”